Bupropion for the Treatment of Methamphetamine Dependence - 1

Completed · Phase 2

Conditions studied: Amphetamine-Related Disorders

In brief

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Key facts

Study ID

NCT00069251

Run by

National Institute on Drug Abuse (NIDA)

People needed

150

Starts

2003-07-01

Expected to finish

2005-06-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
• Subject must be willing to comply with study procedures.
• Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
• Be able to comply with protocol requirements

You may not qualify if…

• Please contact site for more information.

Where it is running

• Matrix Institute on Addictions — Costa Mesa, California, United States
• South Bay Treatment Center — San Diego, California, United States
• Pacific Addiction Research Center — Honolulu, Hawaii, United States
• Powell Chemical Dependency Center — Des Moines, Iowa, United States
• University of Missouri - Kansas City — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.